NCT02911792View on ClinicalTrials.gov

Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration

PHASE4CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

December 20, 2016

Primary Completion Date

July 11, 2023

Study Completion Date

July 11, 2023

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Dapagliflozin

SGLT2 inhibitor

DRUG

Metformin

Oral diabetes medicine that helps control blood sugar levels.

DRUG

Glipizide 5 MG

Oral diabetes medicine that helps control blood sugar levels.

Trial Locations (2)

78207

University Health Systems Texas Diabetic Institute, San Antonio

78229

The University of Texas Health Science Center at San Antonio, San Antonio

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

The University of Texas Health Science Center at San Antonio

OTHER